

Yartemlea® (narsoplimab-wuug) Injection

When requesting Yartemlea (narsoplimab-wuug), the individual requiring treatment must be diagnosed with the following FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-Approved Indication

Yartemlea is indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).

Coverage Guidelines

Transplant-Associated Thrombotic Microangiopathy

The individual must meet all of the following criteria for authorization:

- Is 2 years of age or older;
- Has undergone hematopoietic stem cell transplantation;
- Yartemlea is prescribed by or in consultation with a hematologist, oncologist, transplant specialist physician, or a physician associated with a transplant center.

Approval Duration: 6 months

Dosing Recommendation

The recommended dosage of Yartemlea is provided below:

Weight (kg)	Recommended Dosage
Greater than or equal to 50 kg	370 mg given as an intravenous infusion over 30 minutes once weekly. Increase frequency to twice weekly if there is inadequate improvement in TA-TMA signs and symptoms.
Less than 50 kg	4 mg/kg given as an intravenous infusion over 30 minutes once weekly. Increase frequency to twice weekly if there is inadequate improvement in TA-TMA signs and symptoms.

References

1. Yartemlea® intravenous infusion [prescribing information]. Seattle, WA: Omeros; December 2025.
2. Schoettler ML, Gavrilaki E, Carreras E, et al, on behalf of the American Society for Transplantation and Cellular Therapy. An ASTCT, CIBMTR, EBMT and APBMT consensus statement defining response criteria for hematopoietic cell transplantation associated thrombotic microangiopathy (TA-TMA) directed therapy. *Transplant Cell Ther.* 2025;31(9):610-623.